Review




Structured Review

Proteintech ck7
Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers <t>(CK7,</t> Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
Ck7, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 48 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ck7/product/Proteintech
Average 95 stars, based on 48 article reviews
ck7 - by Bioz Stars, 2026-03
95/100 stars

Images

1) Product Images from "Probiotic-inspired hybrid nanovesicles for enhancing immune checkpoint therapy efficiency via tumor immune microenvironment modulation"

Article Title: Probiotic-inspired hybrid nanovesicles for enhancing immune checkpoint therapy efficiency via tumor immune microenvironment modulation

Journal: Bioactive Materials

doi: 10.1016/j.bioactmat.2025.10.012

Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
Figure Legend Snippet: Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.

Techniques Used: Activity Assay, Ex Vivo, Staining, Derivative Assay, Expressing, Co-Culture Assay



Similar Products

90
Bioss anti ck7
Anti Ck7, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ck7/product/Bioss
Average 90 stars, based on 1 article reviews
anti ck7 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

95
Proteintech ck7
Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers <t>(CK7,</t> Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
Ck7, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ck7/product/Proteintech
Average 95 stars, based on 1 article reviews
ck7 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

94
Proteintech anti ck7
Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers <t>(CK7,</t> Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
Anti Ck7, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ck7/product/Proteintech
Average 94 stars, based on 1 article reviews
anti ck7 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
Proteintech cytokeratin 7 ck7
Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers <t>(CK7,</t> Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
Cytokeratin 7 Ck7, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cytokeratin 7 ck7/product/Proteintech
Average 94 stars, based on 1 article reviews
cytokeratin 7 ck7 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
Proteintech antibodies against cytokeratin 7 ck7
A Hematoxylin and eosin staining of placental tissue. Left: Overall structure (Scale bar: 1000 μm); Right: Magnification of sinusoids (Scale bar: 100 μm). B Immunofluorescence for cluster of differentiation 31 ( CD31 ) (red) and 4′,6-diamidino-2-phenylindole (DAPI) (blue). From left to right: Overview (Scale bar: 1000 μm), CD31 channel, DAPI channel, and merged image (Scale bar: 100 μm). C Immunofluorescence for <t>cytokeratin</t> <t>7</t> ( <t>CK7</t> ) (red) and DAPI (blue). Panels arranged as in B. D Comparison of placental efficiency (fetal-to-placental weight ratio) between groups. E Ratio of labyrinth zone to total area (labyrinth + junction zone). F Quantification of CD31 fluorescence intensity. G Quantification of CK7 fluorescence intensity. Sample size: n = 12 per group (male: female = 1:1). Data expressed as mean ± SEM; Student’s t -test or the non-parametric Wilcoxon rank-sum test.
Antibodies Against Cytokeratin 7 Ck7, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against cytokeratin 7 ck7/product/Proteintech
Average 94 stars, based on 1 article reviews
antibodies against cytokeratin 7 ck7 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

92
Bioss antibody against ck7
A Hematoxylin and eosin staining of placental tissue. Left: Overall structure (Scale bar: 1000 μm); Right: Magnification of sinusoids (Scale bar: 100 μm). B Immunofluorescence for cluster of differentiation 31 ( CD31 ) (red) and 4′,6-diamidino-2-phenylindole (DAPI) (blue). From left to right: Overview (Scale bar: 1000 μm), CD31 channel, DAPI channel, and merged image (Scale bar: 100 μm). C Immunofluorescence for <t>cytokeratin</t> <t>7</t> ( <t>CK7</t> ) (red) and DAPI (blue). Panels arranged as in B. D Comparison of placental efficiency (fetal-to-placental weight ratio) between groups. E Ratio of labyrinth zone to total area (labyrinth + junction zone). F Quantification of CD31 fluorescence intensity. G Quantification of CK7 fluorescence intensity. Sample size: n = 12 per group (male: female = 1:1). Data expressed as mean ± SEM; Student’s t -test or the non-parametric Wilcoxon rank-sum test.
Antibody Against Ck7, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against ck7/product/Bioss
Average 92 stars, based on 1 article reviews
antibody against ck7 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

95
Proteintech mouse anti ck7
A Hematoxylin and eosin staining of placental tissue. Left: Overall structure (Scale bar: 1000 μm); Right: Magnification of sinusoids (Scale bar: 100 μm). B Immunofluorescence for cluster of differentiation 31 ( CD31 ) (red) and 4′,6-diamidino-2-phenylindole (DAPI) (blue). From left to right: Overview (Scale bar: 1000 μm), CD31 channel, DAPI channel, and merged image (Scale bar: 100 μm). C Immunofluorescence for <t>cytokeratin</t> <t>7</t> ( <t>CK7</t> ) (red) and DAPI (blue). Panels arranged as in B. D Comparison of placental efficiency (fetal-to-placental weight ratio) between groups. E Ratio of labyrinth zone to total area (labyrinth + junction zone). F Quantification of CD31 fluorescence intensity. G Quantification of CK7 fluorescence intensity. Sample size: n = 12 per group (male: female = 1:1). Data expressed as mean ± SEM; Student’s t -test or the non-parametric Wilcoxon rank-sum test.
Mouse Anti Ck7, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti ck7/product/Proteintech
Average 95 stars, based on 1 article reviews
mouse anti ck7 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.

Journal: Bioactive Materials

Article Title: Probiotic-inspired hybrid nanovesicles for enhancing immune checkpoint therapy efficiency via tumor immune microenvironment modulation

doi: 10.1016/j.bioactmat.2025.10.012

Figure Lengend Snippet: Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.

Article Snippet: The prepared sections were then stained with anti-CD8α (Abcam, ab237709), CK7 (Proteintech, 17513-1-AP), P63 (Proteintech, 12143-1-AP), Napsin A (ABclonal, A5594), CK5 (Proteintech, 28506-1-AP), and TTF1 (ABclonal, A18128).

Techniques: Activity Assay, Ex Vivo, Staining, Derivative Assay, Expressing, Co-Culture Assay

A Hematoxylin and eosin staining of placental tissue. Left: Overall structure (Scale bar: 1000 μm); Right: Magnification of sinusoids (Scale bar: 100 μm). B Immunofluorescence for cluster of differentiation 31 ( CD31 ) (red) and 4′,6-diamidino-2-phenylindole (DAPI) (blue). From left to right: Overview (Scale bar: 1000 μm), CD31 channel, DAPI channel, and merged image (Scale bar: 100 μm). C Immunofluorescence for cytokeratin 7 ( CK7 ) (red) and DAPI (blue). Panels arranged as in B. D Comparison of placental efficiency (fetal-to-placental weight ratio) between groups. E Ratio of labyrinth zone to total area (labyrinth + junction zone). F Quantification of CD31 fluorescence intensity. G Quantification of CK7 fluorescence intensity. Sample size: n = 12 per group (male: female = 1:1). Data expressed as mean ± SEM; Student’s t -test or the non-parametric Wilcoxon rank-sum test.

Journal: Translational Psychiatry

Article Title: Double-hit of MIA and Nod2 deficiency induces sex-specific offspring behavioral abnormalities through placental dysregulation

doi: 10.1038/s41398-025-03747-z

Figure Lengend Snippet: A Hematoxylin and eosin staining of placental tissue. Left: Overall structure (Scale bar: 1000 μm); Right: Magnification of sinusoids (Scale bar: 100 μm). B Immunofluorescence for cluster of differentiation 31 ( CD31 ) (red) and 4′,6-diamidino-2-phenylindole (DAPI) (blue). From left to right: Overview (Scale bar: 1000 μm), CD31 channel, DAPI channel, and merged image (Scale bar: 100 μm). C Immunofluorescence for cytokeratin 7 ( CK7 ) (red) and DAPI (blue). Panels arranged as in B. D Comparison of placental efficiency (fetal-to-placental weight ratio) between groups. E Ratio of labyrinth zone to total area (labyrinth + junction zone). F Quantification of CD31 fluorescence intensity. G Quantification of CK7 fluorescence intensity. Sample size: n = 12 per group (male: female = 1:1). Data expressed as mean ± SEM; Student’s t -test or the non-parametric Wilcoxon rank-sum test.

Article Snippet: Subsequently, the sections were incubated separately with primary antibodies against cytokeratin 7 ( CK7 ) (1:400, 17513-1-AP; Proteintech) and cluster of differentiation 31 ( CD31 ) (1:400, 28083-1-AP; Proteintech), each diluted in PBS, overnight at 4 °C.

Techniques: Staining, Immunofluorescence, Comparison, Fluorescence